1. Home
  2. SVRN vs NEPH Comparison

SVRN vs NEPH Comparison

Compare SVRN & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OceanPal Inc.

SVRN

OceanPal Inc.

N/A

Current Price

$0.40

Market Cap

41.2M

ML Signal

N/A

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$4.00

Market Cap

45.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVRN
NEPH
Founded
2021
1997
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.2M
45.3M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
SVRN
NEPH
Price
$0.40
$4.00
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
217.7K
42.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
106.67
EPS
N/A
0.10
Revenue
N/A
$14,162,000.00
Revenue This Year
N/A
$33.32
Revenue Next Year
N/A
$12.27
P/E Ratio
N/A
$40.40
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$1.40
52 Week High
$1.47
$6.42

Technical Indicators

Market Signals
Indicator
SVRN
NEPH
Relative Strength Index (RSI) 15.90 46.50
Support Level N/A $3.48
Resistance Level $1.35 $4.27
Average True Range (ATR) 0.05 0.36
MACD -0.00 0.04
Stochastic Oscillator 11.04 60.33

Price Performance

Historical Comparison
SVRN
NEPH

About SVRN OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: